Implementing CER: what will it take?
- PMID: 22663296
- PMCID: PMC10437800
- DOI: 10.18553/jmcp.2012.18.s5-a.S19
Implementing CER: what will it take?
Abstract
Background: Comparative effectiveness research (CER) is undeniably changing how drugs are developed, launched, priced, and reimbursed in the United States. But most organizations are still evaluating what CER can do for them and how and when they can utilize the data. A roundtable of stakeholders, including formulary decision makers, evaluated CER's possible effects on managed care organizations (MCOs) and what it may take to fully integrate CER into decision making.
Objectives: To examine the role of CER in current formulary decision making, compare CER to modeling, discuss ways CER may be used in the future, and describe CER funding sources.
Summary: While decision makers from different types of organizations, such as pharmacy benefit management (PBM) companies and MCOs, may have varying definitions and expectations of CER, most thought leaders from a roundtable of stakeholders, including formulary decision makers, see value in CER's ability to enhance their formulary decision making. Formulary decision makers may be able to use CER to better inform their coverage decisions in areas such as benefit design, contracting, conditional reimbursement, pay for performance, and other alternative pricing arrangements. Real-world CER will require improvement in the health information technology infrastructure to better capture value-related information. The federal government is viewed as a key driver and funding source behind CER, especially for infrastructure and methods development, while industry will adapt the clinical development and create increasing CER evidence. CER then needs to be applied to determining value (or cost efficacy).
Conclusions: It is expected that CER will continue to grow as a valuable component of formulary decision making. Future integration of CER into formulary decision making will require federal government and academic leadership, improvements in the health information technology infrastructure, ongoing funding, and improved and more consistent methodologies.
Similar articles
-
Can CER be an effective tool for change in the development and assessment of new drugs and technologies?J Manag Care Pharm. 2012 Jun;18(5 Supp A):S06-11. doi: 10.18553/jmcp.2012.18.s5-a.s06. J Manag Care Pharm. 2012. PMID: 22663293 Free PMC article.
-
Looking at CER from the managed care organization perspective.J Manag Care Pharm. 2012 May;18(4 Suppl A):S13-6. doi: 10.18553/jmcp.2012.18.S8-A.S13. J Manag Care Pharm. 2012. PMID: 22578213 Free PMC article.
-
Bringing liraglutide to market: a CER case study.J Manag Care Pharm. 2012 Jun;18(5 Supp A):S12-8. doi: 10.18553/jmcp.2012.18.s5-a.S12. J Manag Care Pharm. 2012. PMID: 22663295 Free PMC article.
-
The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.Pain Physician. 2011 May-Jun;14(3):E249-82. Pain Physician. 2011. PMID: 21587337 Review.
-
Investigation of comparative effectiveness research in Asia, Europe, and North America.Indian J Pharmacol. 2015 Nov-Dec;47(6):585-93. doi: 10.4103/0253-7613.169592. Indian J Pharmacol. 2015. PMID: 26729947 Free PMC article. Review.
Cited by
-
Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges.J Manag Care Spec Pharm. 2016 Jun;22(6):609-16. doi: 10.18553/jmcp.2016.22.6.609. J Manag Care Spec Pharm. 2016. PMID: 27231789 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources